Second-line treatment in advanced gastric cancer : Data from the Spanish AGAMENON registry
Cotes Sanchís, Almudena (Hospital General Universitario de Elda)
Gallego Plazas, Javier (Hospital General Universitario de Elche)
Hernandez, Raquel (Hospital Universitario de Canarias (La Laguna))
Arrazubi, Virginia (Complejo Hospitalario de Navarra)
Custodio, Ana (Hospital Universitario La Paz (Madrid))
Cano, Juana María (Hospital General Universitario de Ciudad Real)
Aguado, Gema (Hospital General Universitario Gregorio Marañón)
Macias Declara, Ismael (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
López-López, Carlos A. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
López, Flora (Hospital Universitario 12 de Octubre (Madrid))
Visa, Laura (Hospital Universitario El Mar)
Garrido, Marcelo (Pontificia Universidad Católica de Chile)
Martínez Lago, Nieves (Complejo Hospitalario Universitario de A Coruña)
Fernández Montes, Ana (Complejo Hospitalario Universitario de Ourense)
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Azkárate, Aitor (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Pimentel, Paola (Hospital General Universitario Santa Lucía (Cartagena, Múrcia))
Reguera, Pablo (Hospital Universitario Ramón y Cajal (Madrid))
Ramchandani, Avinash (Hospital Universitario Insular de Gran Canaria)
Cacho Lavin, Diego (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Martín Carnicero, Alfonso (Hospital San Pedro de Alcántara)
Granja, Mónica (Hospital Universitario Clínico San Carlos (Madrid))
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau)
Hernández Pérez, Carolina (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife))
Hurtado-Nuño, Alicia (Hospital Universitario Fundación Alcorcón)
Serra, Olbia (Institut Català d'Oncologia)
Buxo, Elvira (Hospital Universitari Vall d'Hebron)
Vidal Tocino, Rosario (Complejo Asistencial Universitario de Salamanca)
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias)
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia))
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). 2311 cases with 2066 progression events since first-line (89. 3%) were recorded; 245 (10. 6%) patients died during first-line treatment and 1326/2066 (64. 1%) received a second-line. Median PFS-2 and PPS were 3. 1 (95% CI, 2. 9-3. 3) and 5. 8 months (5. 5-6. 3), respectively. The most widely used strategies were monoCT (56. 9%), polyCT (15. 0%), ramucirumab+CT (12. 6%), platinum-reintroduction (8. 3%), trastuzumab+CT (6. 1%), and ramucirumab (1. 1%). PFS-2/PPS medians gradually increased in monoCT, 2. 6/5. 1 months; polyCT 3. 4/6. 3 months; ramucirumab+CT, 4. 1/6. 5 months; platinum-reintroduction, 4. 2/6. 7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5. 2/11. 7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's τ = 0. 613), lower in those subjects who received second-line (Kendall's τ = 0. 539), especially with ramucirumab+CT (Kendall's τ = 0. 413). This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	PloS one, Vol. 15 Núm. 7 July (july 2020) , p. e0235848, ISSN 1932-6203

DOI: 10.1371/journal.pone.0235848
PMID: 32735623

16 p, 1.6 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles